FBIO
Fortress Biotech, Inc.Company Information
- Company Name
- Fortress Biotech, Inc.
- CIK
- CIK0001429260
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- FBIO: Nasdaq, FBIOP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- FBIO
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-09-23
- Last sale
- 2024-05-20
- Shares purchased (TTM)
- 2,673,432
- Shares sold (TTM)
- 10,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 4,943,255
- Shares outstanding
- 31,791,173
- Ownership
- 15.55%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -8.72%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Affiliates | -0 | 1 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 197 | 256 | 79 | 86 | 74 | 91 | 57 | 59 | 76 | 84 | 81 | 72 | ||||||
| Accounts Receivable Net Current | 36 | 25 | 30 | 18 | 16 | 18 | 10 | 11 | 10 | 10 | 15 | 8 | ||||||
| Inventory Net | 8 | 9 | 10 | 12 | 13 | 12 | 14 | 12 | 10 | 11 | 10 | 11 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 5 | 5 | 2 | 7 | 5 | 7 | 3 | 5 | 12 | 11 | 6 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | 0 | 0 | 0 | - | 1 | - | - | - | - | - | ||||||
| Assets Current | 246 | 295 | 124 | 119 | 110 | 127 | 90 | 86 | 103 | 117 | 117 | 98 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 6 | 7 | 7 | ||||||
| Operating Lease Right Of Use Asset | 11 | 12 | 12 | 12 | 13 | 13 | 14 | 14 | 15 | 16 | 17 | 18 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Equity Securities F V N I Noncurrent | 29 | 19 | 18 | - | - | - | 3 | - | - | - | - | - | ||||||
| Finite Lived Intangible Assets Net | 26 | 26 | 28 | 29 | 30 | 31 | 32 | 18 | 19 | 19 | 20 | 21 | ||||||
| Other Assets Noncurrent | 1 | 1 | 0 | 18 | 3 | 3 | 1 | 3 | 3 | 4 | 4 | 5 | ||||||
| Assets | 317 | 357 | 186 | 181 | 160 | 178 | 144 | 127 | 146 | 165 | 168 | 151 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 49 | 93 | 47 | 45 | 49 | 66 | 66 | 64 | 69 | 76 | 74 | 81 | ||||||
| Taxes Payable Current | 5 | 5 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Derivative Liabilities Current | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | 2 | ||||||
| Convertible Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Other Liabilities Current | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 1 | ||||||
| Liabilities Current | 62 | 103 | 50 | 54 | 58 | 74 | 71 | 70 | 76 | 88 | 85 | 97 | ||||||
| Long Term Notes Payable | 35 | 37 | 52 | 48 | 50 | 56 | 58 | 52 | 67 | 61 | 61 | 46 | ||||||
| Operating Lease Liability Noncurrent | 11 | 12 | 13 | 13 | 13 | 14 | 15 | 15 | 16 | 18 | 18 | 19 | ||||||
| Other Liabilities Noncurrent | 3 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities | 111 | 155 | 123 | 116 | 123 | 146 | 146 | 140 | 160 | 169 | 166 | 164 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 788 | 786 | 784 | 786 | 780 | 774 | 764 | 755 | 739 | 733 | 717 | 702 | ||||||
| Retained Earnings Accumulated Deficit | -624 | -624 | -734 | -730 | -736 | -751 | -741 | -734 | -721 | -710 | -695 | -686 | ||||||
| Stockholders Equity | 206 | 162 | 62 | 56 | 44 | 22 | -2 | -13 | -15 | 23 | 23 | -13 | ||||||
| Minority Interest | 42 | 40 | 12 | 9 | -7 | 10 | -24 | -34 | -32 | -27 | -21 | -30 | ||||||
| Liabilities And Stockholders Equity | 317 | 357 | 186 | 181 | 160 | 178 | 144 | 127 | 146 | 165 | 168 | 151 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | ||||||
| Preferred Stock Shares Issued | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Preferred Stock Shares Outstanding | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Preferred Stock Liquidation Preference | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 33 | 33 | 31 | 31 | 30 | 30 | 28 | 28 | 23 | 19 | 15 | 9 | ||||||
| Shares Outstanding | 33 | 33 | 31 | 31 | 30 | 30 | 28 | 28 | 23 | 19 | 15 | 9 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialFortress Biotech, Inc. (FBIO) — SEC Financial Statements & Analysis
Fortress Biotech, Inc. (FBIO) is a pharmaceutical preparations company, incorporated in DE. Fortress Biotech, Inc. trades on Nasdaq as: FBIO, FBIOP. Fortress Biotech, Inc. (FBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Fortress Biotech, Inc. carries a market cap of $97.28M, a P/E ratio of 0.56x, a P/B ratio of 0.47x, a P/S ratio of 1.46x, an enterprise value of $-65.91M, and an EV/EBITDA multiple of 2.29x. On profitability, it posts a gross margin of 64.76%, an operating margin of -43.64%, a net margin of 257.63%, a Return on Equity (ROE) of 137.78%, a Return on Assets (ROA) of 72.27%, and a Return on Invested Capital (ROIC) of -88.60%. Per share, it reports EPS of $5.42, diluted EPS of $5.42, free cash flow per share of $3.96, and a dividend per share of $0.02. Over the trailing year, it posted revenue growth of 20.68% year-over-year, net income growth of -407.67% year-over-year, and EPS growth of -360.14% year-over-year. On the balance sheet, it maintains a current ratio of 3.96x, a quick ratio of 3.76x, working capital of $183.49M, a debt-to-equity ratio of 0.54x, a debt ratio of 0.35, an interest coverage ratio of -19.77x, free cash flow of $125.84M (TTM), and net debt of $-163.19M. Figures sourced from SEC EDGAR.
- Market Cap
- $97.28M
- P/E TTM
- 0.56x
- EPS TTM
- $5.42
- P/B TTM
- 0.47x
- ROE TTM
- 137.78%
- ROA TTM
- 72.27%
- Debt To Equity
- 0.54x
- Free Cash Flow TTM
- $125.84M
- Net Revenue TTM Growth 1Y
- 20.68%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Fortress Biotech, Inc. in?
Fortress Biotech, Inc. (FBIO) operates in the Pharmaceutical Preparations industry.
What exchange does FBIO trade on?
Fortress Biotech, Inc. (FBIO) trades on the Nasdaq.
Where is Fortress Biotech, Inc. incorporated?
Fortress Biotech, Inc. is incorporated in DE.
When was Fortress Biotech, Inc. (FBIO)'s most recent SEC filing?
Fortress Biotech, Inc. (FBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is FBIO's market cap?
Fortress Biotech, Inc. (FBIO) has a market capitalization of $97.28M as of 2026-06-30.
What is FBIO's P/E ratio?
Fortress Biotech, Inc. (FBIO)'s trailing twelve month P/E ratio is 0.56x as of 2026-06-30.
What is FBIO's EPS (earnings per share)?
Fortress Biotech, Inc. (FBIO)'s trailing twelve month EPS is $5.42 as of 2026-06-30.
What is FBIO's ROE (return on equity)?
Fortress Biotech, Inc. (FBIO)'s trailing twelve month Return on Equity (ROE) is 137.78% as of 2026-06-30.
What is FBIO's ROA (return on assets)?
Fortress Biotech, Inc. (FBIO)'s trailing twelve month Return on Assets (ROA) is 72.27% as of 2026-06-30.
What is FBIO's ROIC (return on invested capital)?
Fortress Biotech, Inc. (FBIO)'s trailing twelve month Return on Invested Capital (ROIC) is -88.60% as of 2026-06-30.
What is FBIO's EV/EBITDA?
Fortress Biotech, Inc. (FBIO)'s trailing twelve month EV/EBITDA is 2.29x as of 2026-06-30.